Answers are grounded in this paper and cite their sources.
These findings provide promising first-in-human clinical experience for intracranial administration of IL13Rα2-specific CAR T cells for the treatment of GBM, establishing a foundation on which future refinements of adoptive CAR T-cell therapies can be applied.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: